Outcome measure | Intra-arterial arm N (%), unweighted | Medical arm N (%), unweighted | OR (95% CI) or p value |
---|---|---|---|
Included studies with LVO confirmed at time of randomization (dataset 1) | |||
Primary outcome: | |||
mRS 0–2 at 90 days | 251 (38.3%) | 136 (25.8%) | 1.67 (1.29 to 2.16), p=0.0001 |
Secondary outcomes: | |||
mRS 0–1 at 90 days | 156 (23.8%) | 66 (12.5%) | 1.93 (1.39 to 2.68), p<0.0001 |
mRS 0–3 at 90 days | 348 (53.1%) | 224 (42.4%) | 1.46 (1.16 to 1.85), p=0.002 |
Mortality at 90 days | 122 (18.6%) | 114 (21.6%) | 0.80 (0.60 to 1.07), p=0.13 |
mRS shift analysis | Mean 3.35 | Mean 3.73 | p<0.0001 |
All included studies (dataset 2) | |||
Primary outcome: | |||
mRS 0–2 at 90 days | 419 (39.1%) | 271 (32.6%) | 1.27 (1.04 to 1.54), p=0.018 |
Secondary outcomes: | |||
mRS 0–1 at 90 days | 270 (25.2%) | 169 (20.3%) | 1.22 (0.97 to 1.53), p=0.09 |
mRS 0–3 at 90 days | 600 (56.0%) | 412 (49.5%) | 1.25 (1.04 to 1.51), p=0.019 |
Mortality at 90 days | 203 (19.0%) | 156 (18.8%) | 0.96 (0.76 to 1.22), p=0.73 |
mRS shift analysis | Mean mRS 3.16 | Mean mRS 3.42 | p=0.003 |
LVO, large vessel occlusion; mRS, modified Rankin Scale score.